The Germans Trias Research Institute and ICO Badalona describe genomic alterations that may help predict treatment response in an aggressive type of breast cancer
Researchers at IGTP, HUGTiP and ICO Badalona have identified genetic alterations, including frequent TP53 mutations, that could serve as biomarkers to guide treatment decisions in HER2-positive breast cancer.
